A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia

International Journal of Neuropsychopharmacology

Volumn 12, Issue 2, 2009, Pages 191-199

  Mizukami, Katsuyoshi ^a   Asada, Takashi ^a   Kinoshita, Toru ^b   Tanaka, Katsuaki ^c   Sonohara, Kazuki ^c   Nakai, Ryuhei ^d   Yamaguchi, Kiyoshi ^e   Hanyu, Haruo ^f   Kanaya, Kiyoshi ^f   Takao, Tetsuya ^g   Okada, Masakatsu ^h   Kudo, Sumio ⁱ   Kotoku, Hayato ^j   Iwakiri, Masahiko ^k   Kurita, Hirofumi ^l   Miyamura, Toshihiro ^m   Kawasaki, Yosuke ⁿ   Omori, Koji ^o   Shiozaki, Kazumasa ^p   Odawara, Toshinari ^p   Suzuki, Tatsuya ^q   Yamada, Shizuru ^r   Nakamura, Youichi ^s   Toba, Kenji ^c   more..

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Kodama Clinic   (Japan)

^c KYORIN UNIVERSITY   (Japan)

^d Kikyogahara Hospital   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g Hospital Bando   (Japan)

^h Hitachi Umegaoka Hospital   (Japan)

ⁱ Hitachi Sakura Clinic   (Japan)

^j Luria mental Clinic   (Japan)

^k Ishizaki Hospital   (Japan)

^l Kurita Hospital   (Japan)

^m UNIVERSITY OF YAMANASHI   (Japan)

ⁿ Kyosai Hospital   (Japan)

^o Gunma Prefectural Psychiatric Medical Center   (Japan)

^p YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^q NIPPON MEDICAL SCHOOL   (Japan)

^r Geriatric Facilities Mahoroba no sato   (Japan)

^s Nakamura Clinic   (Japan)

more..

Author keywords

Behavioural and psychological symptoms of dementia; Traditional Japanese medicine (kampo); Yokukansan

Indexed keywords

KAMPO; TJ 54; UNCLASSIFIED DRUG; YOKUKANSAN; HERBACEOUS AGENT; YOKU KAN SAN; YOKU-KAN-SAN;

ADRENAL CORTEX DISEASE; ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BARTHEL INDEX; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; EVALUATION; FEMALE; HALLUCINATION; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; IRRITABILITY; JAPANESE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MINI MENTAL STATE EXAMINATION; NAUSEA; OUTPATIENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PSEUDOALDOSTERONISM; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RATING SCALE; SEDATION; SIDE EFFECT; SYMPTOM; TRADITIONAL MEDICINE; VOMITING; BEHAVIOR; CHINESE MEDICINE; DEMENTIA; DRUG SCREENING; EPIDEMIOLOGY; JAPAN; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; BEHAVIORAL SYMPTOMS; BIAS (EPIDEMIOLOGY); CROSS-OVER STUDIES; DEMENTIA; DRUG EVALUATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; JAPAN; MALE; MEDICINE, CHINESE TRADITIONAL; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; STATISTICS, NONPARAMETRIC;

EID: 67049173445     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570800970X     Document Type: Article

References (29)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, D.C.: American Psychiatric Association.
2. Beeri MS, Werner P, Davidson M, Noy S (2002). The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. International Journal of Geriatric Psychiatry 17, 403-408.
3. Cantillon M, Brunswick R, Molina D, Bahro M (1996). Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. American Journal of Geriatric Psychiatry 4, 263-267.
4. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
5. Egashira N, Iwasaki K, Ishibashi A, Hayakawa K, Okuno R, Abe M, Uchida N, Mishima K, Takasaki K, Nishimura R, Oishi R, Fujiwara M (2008). Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32, 1516-1520.
6. Folstein MF, Folstein SE, McHugh PR (1975). Mini-Mental State: a practical method for grading the cognitive state of patients for
7. Herrmann N, Lanctôt KL (2006). Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Safety 29, 833-843.
8. Iwasaki K, Kabayashi S, Chimura Y, Taguchi M, Inoue K, Cho S, Akiba T, Arai H, Cyong JC, Sasaki H (2004). A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine 'BaWei Di Huang Wan' in the treatment of dementia. Journal of American Geriatric Society 52, 1518-1521.
9. Iwasaki K, Maruyama M, Tomita N, Furukawa K, Nemoto M, Fujiwara H, Seki T, Fujii M, Kodama M, Arai H (2005a). Effects of the traditional Chinese medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. Journal of Clinical Psychiatry 66, 1612-1613.
10. Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, Tanji H, Fujiwara H, Seki T, Fujii M, Arai H, Sasaki H (2005b). A randomized, observer-blinded, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in patients with dementia. Journal of Clinical Psychiatry 66, 248-252.
11. Jones B, Kenward MG (1989). Design and Analysis of Cross-over Trials. London: Chapman & Hall.
12. Kanatani H, Kohda H, Yamasaki K, Hotta I, Nakata Y, Segawa T, Yamanaka E, Aimi N, Sakai S (1985). The active principles of the branchlet and hook of Uncaria sinensis Oliv. examined with a 5-hydroxytryptaomine receptor binding assay. Journal of Pharmacy and Pharmacology 37, 401-404.
13. Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, Chen CP (2003). Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer's disease. Brain Research 974, 82-87.
14. Lawlor BA (2004). Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. Journal of Clinical Psychiatry 65 (Suppl. 11), 5-10.
15. Lawton MP, Brody EM (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
16. Liao JF, Jan YM, Huang SY, Wang HH, Yu LL, Chen CF (1995). Evaluation with receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs. Proceedings of the National Science Council, Republic of China B 19: 151-158.
17. Mahoney FI, Barthel DW (1965). Functional evaluation: the Barthel Index. Maryland State Medical Journal 14, 61-65.
18. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of health and human services task force on Alzheimer's Disease. Neurology 34, 939-944.
20. 1 receptor. Pharmacology Biochemistry and Behavior 81, 616-625.
21. 1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. International Journal of Neuropsychopharmacology 10, 281-283.
22. Schneider LS, Dagerman K, Insel PS (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 14, 191-210.
23. Schneider LS, Dagerman KS, Insel P (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 294, 1934-1943.
24. Steele C, Rovner B, Chase GA, Folstein M (1990). Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 147, 1049-1051.
25. Takeda A, Itoh H, Tamano H, Yuzurihara M, Oku N (2008). Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-defficient rats. Nutritional Neuroscience 11, 41-46.
26. Terasawa K, Shimada Y, Kita T (1997). Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine 4, 15-22.
27. Verbeke G, Molenberghs G (2000). Linear Mixed Models for Longitudinal Data. New York: Springer, p. 68.
28. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 353, 2335-2341.
29. Yamaguchi S, Matsubara M, Kobayashi S (2004). Event-related brain potential changes after Choto-san administration in stroke patients with mild cognitive impairments. Psychopharmacology 171, 241-249.